myLaminin Perspectives

A practical guide to building a CTMS business case focusing on ROI, operational efficiency, visibility, accountability, compliance, and risk reduction. Learn how clinical research organizations, academic medical centers, universities, CROs, and research institutions can quantify the cost of manual trial management and evaluate how a modern CTMS can improve study start-up, site performance, audit readiness, and research operations nationwide.

Five years ago, myLaminin began with a single idea. Today, it has evolved into a connected research ecosystem supporting the complete research lifecycle—from grant submission through publication. Discover how one conversation with a Canadian U15 university transformed our vision, how researchers co-designed our platform, and how myLaminin became a sovereign Research Data Management (RDM) and Clinical Trial Management System (CTMS) built for active science.

The new ICH E6(R3) guidelines are transforming clinical research worldwide, requiring Quality-by-Design, risk-based oversight, and validated digital systems. Discover how myLaminin's co-designed Clinical Trial Operations (CTOps) and CTMS platform helps research teams, principal investigators, administrators, and compliance professionals streamline operations, strengthen data integrity, improve audit readiness, and meet evolving global regulatory requirements with confidence.

Learn the differences between CTMS, EDC, and eTMF and how these essential clinical trial systems work together to improve research operations, data quality, regulatory compliance, and study efficiency. This guide explains the role of each platform, their integration across the clinical trial lifecycle, and how myLaminin's Research Data Management platform combines CTMS capabilities, participant management, eTMF, protocol management, audit trails, and 21 CFR Part 11 compliant

Discover how Clinical Trial Management Systems (CTMS) help academic research institutions improve compliance, reduce administrative burden, accelerate study start-up, and support ICH E6(R3)-aligned clinical trial operations.

earn how sponsors can manage protocol deviations, amendments, eTMF documentation, and regulatory compliance in multi-site clinical trials under evolving ICH E6(R3) expectations.

Clinical trial start-up delays continue to impact site activation, budgets, and timelines due to fragmented workflows across feasibility, contracting, IRB/REB approvals, training, and system readiness. This article explains how CTMS platforms, integrated research systems, and AI-driven automation reduce inefficiencies by centralizing processes, improving visibility, and accelerating trial activation across global clinical research environments.

Running clinical trials without a Clinical Trial Management System (CTMS) creates hidden operational burdens, from fragmented data and compliance risks to poor collaboration and reduced patient engagement. Disconnected tools like spreadsheets and email slow execution, increase errors, and threaten data integrity. A centralized CTMS streamlines workflows, ensures regulatory compliance, and improves trial efficiency, making it essential for scalable, secure, and successful clin

Rising clinical trial costs are driven by growing protocol complexity, recruitment challenges, site capacity limits, regulatory burdens, and expanding data demands. These inefficiencies strain sponsors and delay outcomes. By adopting quality-by-design, optimizing protocols, improving patient engagement, and leveraging integrated CTMS and RDM platforms, organizations can reduce costs, enhance compliance, and accelerate clinical research while maintaining data integrity.